Ankura™ TAA Stent Graft System Post-Market Clinical Follow-up Study

Inclusion Criteria:

• Patient has descending thoracic aortic aneurysm (DTA) or type B aortic dissection (TBAD), who needs endovascular repair (TEVAR).

• Life expectancy > 1 year.

• Patient or legally authorized representative understands the nature of the clinicaltrial, agrees to its provisions, agrees to comply with the requirements of the studyincluding a 3-year follow-up, and signed applicable Informed Consent Form.

• Patient's characteristics consistent with Ankura™ Stent Graft System IFU and sizingguidelines, which indicate as following:

1. For descending thoracic aortic aneurysm (DTA) patient:

• Adequate iliac/femoral access vessel that is compatible with the requireddelivery system.
• Aortic inner diameter in the range of 18-42mm.
• ≥15mm non-aneurysmal aorta proximal and distal to the lesion.
• Morphology suitable for endovascular repair.

2. For type B aortic dissection (TBAD) patient:

• Adequate iliac/femoral access vessel that is compatible with the requireddelivery system.
• ≥15mm landing zone proximal to the primary entry tear; proximal extent ofthe landing zone must not be dissected. Diameter at proximal extent ofproximal landing zone in the range of 16-44mm.
• ≥15mm landing zone distal to the primary entry tear; distal extent of thelanding zone must not be dissected. Diameter at distal extent of distallanding zone in the range of 16-44mm.
• Morphology suitable for endovascular repair.

Exclusion Criteria:

• Patient with any contraindications mentioned in the Ankura™ Stent Graft System IFU:

• Patients with acute systemic infection;

• Patients who have had other devices implanted in the cardiovascular cavity,which will interfere with the placement of this device;

• Patients with mesenteric blood flow mainly supplied by the inferior mesentericartery;

• Patients who have allergic reaction to the device;

• Patients who are not suitable for endovascular repair in vascular morphology;

• Patients who cannot tolerate contrast agents due to severe renal insufficiency;

• Patients who are allergic to contrast agents;

• Aneurysms neck with thrombus;

• Non-aneurysmal aortic proximal neck length <1.5cm;

• Non-aneurysmal aortic distal anchorage zone <1.5cm;

• For aneurysms, Non-aneurysmal aortic diameter <18mm or >42mm. For Type Bdissections, Non-aneurysmal aortic diameter <16mm or >44mm.

• Patient with traumatic aortic injury;

• Patient with uncorrectable coagulopathy;

• Patient with hereditary connective tissue disease, including but not limited toMarfan Syndrome or Ehlers-Danlos Syndrome;

• Patient with morbid obesity, weight greater than 350 Pounds (150kg), or who cannotundergo accurate fluoroscopy examination due to obesity;

• Age<18 Years or Age> 85 Years;

• Pregnant or plan to be pregnant or breast feeding;

• Myocardial infarction or stroke within 3 months prior to the procedure;

• American Society of Anesthesiologists Physical Status Classification (ASA)classification 5 or higher;

• Patient with an unstable angina pectoris or hearth insufficiency New York HeartAssociation Functional Classification (NYHA) 3 or 4

• Participant in other drug or medical device clinical trials;

• Patient with access vessel which are to tortuous, narrow or any kind of reasons thatwould lead to failure of introduction and advancing an introducer sheath;

• Any condition (medical or anatomic) which makes the patient not suitable forendovascular repair according to the opinion of the investigator.